View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
August 25, 2016

Pharma Technology Focus – Issue 50

In this issue: Maximising investment by cancer megafunds, positive clinical trials for an antibody to treat lupus, how copper can be used to tackle obesity, whether day and night should influence our drug regimes, a device to soak up excess drugs and more.

By Susanne Hauner

Pharma Technology Focus is free for the iPad. Download our app to read the latest issue and browse our back issues for free.

A team of researchers has devised a method to maximise investment and reduce risk in cancer megafunds through identifying ‘toxic assets’ that threaten the fund. We investigate the optimal financial strategy to increase the likelihood that an investment is paying off scientifically.

We also take a look at AstraZeneca’s new treatment for lupus, find out how copper could be used to treat illnesses such as obesity, and review research that suggests there may be benefits to timing chemotherapy in cancer patients to align with the body’s inner clock.

Plus, we find out about a device that can be used to soak up excess harmful drugs, explore a new path of drug development in the battle against colorectal cancers, learn how researchers who have made ethical errors can be rehabilitated, and hear from a roundtable of experts about how pharma companies can benefit from outsourcing regulatory and pharmacovigilance activities.

Read the issue for free on your iPad through our app, or if you're on a desktop computer you can also read it in our web viewer.

In this issue

Making the Right Investment By directing resources away from research projects with zero chance of success, a new financial engineering model could accelerate cancer drug discovery. Elly Earls meets the man behind the method, Bud Mishra, to find out how. Read the article.

Trialling a New Treatment AstraZeneca has presented positive clinical trial results for anifrolumab, a monoclonal antibody under development for the treatment of lupus. Abi Millar finds out more from Dr Richard Furie, principal investigator. Read the article.

Curing with Copper According to new research from the University of California, Berkeley, copper plays an essential role in fat metabolism, breaking down fat cells so they can be used for energy. Abi Millar finds out more. Read the article.

Watching the Clock Our bodies act differently at different times of day, but why then are so few drugs designed with our natural biorhythms in mind? Abi Millar finds out more from Washington State University’s Professor Shobhan Gaddameedhi. Read the article.

Capturing Excess Drugs A new device that can capture excess chemotherapy drugs by their electric charge could revolutionise cancer treatment. Elly Earls meets the researchers behind the innovation to find out how. Read the article.

Taking a Different Path A new path of drug development could see exciting potential in the battle against colorectal cancers. Andrew Putwain attended the ESMO World Congress on Gastrointestinal Cancer to find out more. Read the article.

The New Role of the Affiliate As pharmaceutical companies adapt their regulatory and business processes to respond to a shifting regulatory landscape, they’ve turned their attention to the role of the country affiliate office. Kimty Bui-Van discusses regulatory authorities’ changing expectations with regard to that affiliate role. Read the article.

Rehabilitating Rule-breakers The Professionalism and Integrity Program was developed to help researchers who have made ethical and professional failures to change their ways. Chris Lo finds out more from course director Dr James DuBois. Read the article.

Getting Smarter A recent report estimated that the global smart packaging market will hit $39.7bn by 2020. Liz Wilks at Asia Pulp and Paper explains why the pharma industry is a trailblazer in smart packaging. Read the article.

Next issue preview

Despite some recent positive developments including the Pharmacy Guild’s historic agreement with the government, a report by PwC slams the Australian pharma industry as inefficient for stakeholders, taxpayers, government and patients. We find out what’s going wrong and how to fix it.

We also profile India’s biosimilars market in the wake a legislation changes that open pathways for sale abroad, explore the latest innovations in painkillers that don’t rely on addictive opioids, and find out why Novavax was recently named as one of the top companies to work for.

Plus, we take a closer look at a Canadian study that has shown the efficacy of a combination of chemotherapy and stem cell transplants to treat aggressive multiple sclerosis, and find out how a large-scale effort in the US to personalise medicine could make treatments more targeted and drive the direction of future drug development.

Digital magazine FAQ

You can read Pharma Technology Focus for free on the iPad. Download our app from the App Store to read the latest issue and browse the back issues in our archive. Sign up for a free subscription in the app and never miss a new issue.

You can also continue to read the desktop version for free on our web viewer. (Browser compatibility: The web viewer works in the latest two version of Chrome, Firefox and Safari, as well as in Internet Explorer 9 and 10. Some features may not be compatible with older browser versions.)

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology